Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Anti-Snoring Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 07-06-2019
Market Overview
The anesthesia devices market was valued at USD 9,812.9 million in 2018, and it is expected to reach USD 14,783.0 million by 2024, with an anticipated CAGR of 7.11%, during the forecast period, 2019-2024.
The growth in the geriatric population is likely to result in a significant increase in the demand for the surgeries. The overall increase in the number of surgeries performed has a strong impact on the anesthesia devices market, as anesthetic devices are used in surgical procedures to reduce the pain. The geriatric population is highly prone to degenerative diseases and chronic illnesses, which has caused an increased verge on surgeries and therapeutics. This demands for continuous monitoring, and it is thus expected to drive the growth of the anesthesia devices market. Increasing investments in the market, supporting the technological advancements in anesthesia machines and techniques, are having a major impact on market growth, enabling faster deployment in the healthcare industry.
The requirement by the government, for clear documentation of regular and appropriate servicing of the anesthesia machines, including its components, and their proper maintenance, servicing, and repair, is acting as a restraining factor for the growth of the market.
Scope of the Report
As per the scope of this study, anesthesia devices are used to check a patient’s response toward anesthesia during a surgical process. The requirement of these devices depends upon the type of surgery being performed, and it differs in every case. These devices help the anesthetist to monitor the dose of anesthesia.
Key Market Trends
Anesthesia Monitors Sub-segment is Expected to Register a High CAGR in the Forecast Period
Anesthesia monitors are used to recording and display the delivery of anesthetic substances, like gases, drugs, and fluids to the patient. During surgeries, these are used to check the patients’ health and reaction to the indication of anesthesia. The integration of various functionalities, such as oxygen saturation level, carbon dioxide level, heart rate, and blood pressure, coupled with decision support systems and data analysis to aid clinicians to get better insights on their patients, is favoring the market growth.
The geriatric population is expected to reach 1,402.4 million by 2030, with the increasing life expectancy to 78.74 years (the United States). This is expected to have an indirect impact on the demand for anesthesia monitors.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the overall market throughout the forecast period. In the North American region, the United States holds the largest market share, and this is due to the rapid increase in a number of diseases, such as obesity, cardiovascular problems, and different types of cancers, which have contributed to the rise in the number of surgeries of both open as well as minimally invasive types. The increase in the number of minimally invasive surgeries for chronic diseases has helped the growth of the anesthesia devices market in the country.
Competitive Landscape
The anesthesia devices market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. With the rising patient awareness levels and high prevalence of diseases and a rising number of surgeries, few other smaller players are expected to enter into the market in the coming years. Some of the major players of the market are B. Braun Melsungen AG, Medtronic PLC, Draegerwerk AG, Koninklijke Philips NV, and Fisher & Paykel Healthcare, among others.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
Table of Contents
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Technological Advancements in Anesthesia Technology
4.2.2 Increasing Geriatric Population and a Rise in the Number of Surgical Procedures Requiring Anesthesia
4.2.3 Large Patient Pool Due to Chronic Diseases
4.2.4 Increasing Disposable Incomes in Emerging Markets
4.3 Market Restraints
4.3.1 High Cost of Equipment
4.3.2 Difficulties Associated with the Usage of Anesthesia Devices
4.3.3 Reimbursement Issues in Developing Economies
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Product Type
5.1.1 Anesthesia Machines
5.1.1.1 Anesthesia Workstation
5.1.1.2 Anesthesia Delivery Machines
5.1.1.2.1 Portable
5.1.1.2.2 Standalone
5.1.1.3 Anesthesia Ventilators
5.1.1.4 Anesthesia Monitors
5.2 By Disposables and Accessories
5.2.1 Anesthesia Circuits (Breathing Circuits)
5.2.2 Anesthesia Masks
5.2.3 Endotracheal Tubes (ETTs)
5.2.4 Laryngeal Mask Airways (LMAs)
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 B. Braun Melsungen AG
6.1.2 Medtronic PLC
6.1.3 Draegerwerk AG
6.1.4 Ambu A/S
6.1.5 Fisher & Paykel Healthcare
6.1.6 GE Healthcare
6.1.7 Koninklijke Philips NV
6.1.8 Mindray Medical International Limited
6.1.9 Smiths Medical
6.1.10 Teleflex Inc.
7. Market Opportunities and Future Trends
Market Segmentation
- Market Segmentation
By Product Type
Anesthesia Machines
Anesthesia Workstation
Anesthesia Delivery Machines
Portable
Standalone
Anesthesia Ventilators
Anesthesia Monitors
By Disposables and Accessories
Anesthesia Circuits (Breathing Circuits)
Anesthesia Masks
Endotracheal Tubes (ETTs)
Laryngeal Mask Airways (LMAs)
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe - Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Anti-obesity Drugs Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 07-06-2019
Market Overview
The anti-obesity drugs market is growing steadily with the gradual growth in the number of approvals from the US FDA and Europe EMA. North America, especially the United States, dominates this market, due to better healthcare services and high expenditure, followed by Europe. Till 2012, Xenical (orlistat) and generic phentermine were among the only approved drugs. However, the period between 2012 and 2016 saw high growth in the number of major pharmaceutical companies investing largely on clinical trials.
However, there are still very fewer drugs in the late stage of development. Owing to the less success rate and withdrawal among the centrally acting drugs, several of the major companies have considered the development of anti-obesity drugs as prohibitively risky and shifted the companies’ inclination toward broadening the scope of a diabetic portfolio into obesity. Since several companies have developed a strong relationship between Type 2 diabetes and obesity, it is often considered to be a low-risk strategy and minor investments in the R&D for potential anti-obesity drugs. Currently, the market is gradually growing its authority in the developing regions with the gradual approval of drugs, globally. However, it holds great potential with the aforementioned advantages, as several companies are targeting dual therapy mode for the treatment of obesity.
The Scope of the Report
An ideal anti-obesity drug would help in reducing sustained weight with minimal side effects. Mechanisms that control energy balance have considerable built-in redundancy, overlap with other physiological functions, and are subjected to social and psychological factors that restrict the effectiveness of pharmacological interventions. The anti-obesity drug market is segmented on the basis of the mechanism of action (peripherally acting and centrally acting anti-obesity drugs) and drug type (prescription and OTC drugs).
Key Market Trends
OTC Drugs Segment is Expected to Exhibit Fastest Growth Rate over the Forecast Period
In the present scenario, the weight problem is a major concern, globally. The rising intake of junk food/fast food is resulting in declining healthiness worldwide. As mentioned earlier, obesity is one of the most prevalent problems faced by people of this century. According to WHO, in 2016, more than 1.9 billion adults, ranging between 18 years and older, were overweight. Out of the aforementioned numbers, over 650 million were obese. With intentions to offer weight loss solutions, the companies have developed a number of weight loss products, of which a considerable proportion are OTC drugs.
In most countries, Orlistat is marketed as a prescription drug under the trade name Xenical, by Roche, and it is sold as an OTC drug under the trade name Alli, by GlaxoSmithKline, in the United Kingdom and the United States. Currently, the number of OTC drugs approved in the market is very less. However, the cost-effectiveness and ease of availability of OTC products are expected to propel the growth of the market.
North America Captured the Largest Market Share and is Expected to Retain its Dominance
North America dominated the global anti-obesity drugs market, with the United States accounting for the major contributor to the market. The primary factors driving the growth of the market studied are an increase in obese population and high healthcare spending. In the past few decades, several anti-obesity drugs are withdrawn from the market, due to reported and documented adverse effects. After years of interruption, the US Food and Drug Administration (FDA) has recently approved multiple new anti-obesity drugs. Majority of these medications are administered orally, and only one is administered subcutaneously. According to the data published by the Centers for Disease Control and Prevention (CDC), the prevalence of obesity was 39.8% and affected about 93.3 million US adults in 2015-2016, hence propelling the anti-obesity drugs market.
Competitive Landscape
The presence of major market players, such as GlaxoSmithKline, Novo Nordisk, Pfizer, F Hoffmann-La Roche, and Bayer AG, is, in turn, increasing the overall competitive rivalry of the market. Large organizations rely heavily on advertising expenses and branding strategies, collaborating with successful personality, initiative, or programs at the national levels, which promote their product, and thus are recognized earlier than other brands in the market. With the high prevalence rate of the disease, the intensity of competitive rivalry is moderate to high.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Prevalence of Obesity
4.2.2 Sedentary Lifestyle
4.3 Market Restraints
4.3.1 Availability of Alternative Treatment Options
4.3.2 Side Effects of Drugs
4.3.3 High Drug Development Costs
4.4 Industry Attractiveness- Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 Mechanism of Action
5.1.1 Peripherally Acting Anti-obesity Drugs
5.1.2 Centrally Acting Anti-obesity Drugs
5.2 Drug Type
5.2.1 Prescription Drugs
5.2.2 OTC drugs
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 United Kingdom
5.3.2.2 Germany
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 Arena Pharmaceuticals
6.1.2 GlaxoSmithKline
6.1.3 Nalpropion Pharmaceuticals Inc.
6.1.4 F Hoffmann-La Roche
6.1.5 Vivus
6.1.6 Bayer AG
6.1.7 Novo Nordisk
6.1.8 Pfizer
6.1.9 Eisai
7. Market Opportunities And Future Trends
Market Segmentation
- Mechanism of Action
Peripherally Acting Anti-obesity Drugs
Centrally Acting Anti-obesity Drugs
Drug Type
Prescription Drugs
OTC drugs
Geography
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific - Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Anesthesia Drugs Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 112 pages | Published: 17-06-2019 |
- Healthcare
- Mordor Intelligence
- 112 pages
- Published: 17-06-2019
Market Overview
The anesthesia drugs market was valued at USD 4,512.11 million in 2018, and is estimated to be valued at USD 5,314.66 million in 2024, while witnessing a CAGR of 4.20% over the forecast period of 2019-2024. The key factors propelling the growth of this market are the increasing number of surgeries and new approvals of anesthetic drugs.
There are wide ranges of surgeries based on the length of stay for surgeries. These include elective surgery and emergency surgery. Based on procedures, there are wide ranges of surgeries, where open surgery is most common. Others include keyhole surgery, laparoscopic surgery, microsurgery, and cosmetic surgery. In recent years, several articles have reported a significant rise in the number of day care procedures (ambulatory surgery), and diagnostic and therapeutic services. This is primarily due to the increased dependence on advances made in anesthesia, surgical, and medical technologies.
Furthermore, the rise in surgeries is attributed to the increasing risk of various accidents, sports injuries, and diseases, globally. According to the Center of Disease Control and Prevention (CDC), more than 51 million inpatient surgeries and 53 million outpatient surgeries were performed in the United States in 2017. In the European region, in England, nearly 4.7 million patients were admitted for surgeries in 2014, as per the Royal College of Surgeons. This indicates the rising number of surgeries, which ultimately results into the rising demand for the anesthesia drugs and propels the growth of the anesthesia drugs market.
Scope of the Report
Anesthesia is a drug that causes a reversible loss of sensation. There are several types of anesthetic drugs available in the market, such as general anesthesia, spinal anesthesia, IV regional anesthesia, local anesthesia, peripheral nerve block, and saddle block or caudal anesthesia.
Key Market Trends
Propofol Sub-segment is Expected to Show the Fastest Growth in the General Anesthesia Drugs Segment
The propofol sub-segment of the anesthesia drugs market is expected to experience a fast growth rate while witnessing a CAGR of 4.20% over the forecast period.
Propofol is a drug that has been used for a long time for various surgical procedures requiring anesthesia. Teva Pharmaceuticals had stopped manufacturing propofol for a particular time; however, the drug returned to the market in 2013. Hospira is another major player in the propofol sub-segment. In 2015, Pfizer acquired Hospira and created a leading global established pharmaceutical (GEP) business. Some of the companies who manufacture propofol injections are Neon Laboratories Limited, Bharat Serums and Vaccines Limited, and Fresenius Kabi. The drug is always in demand in the market for utilization in different surgeries, and is expected to witness rapid growth in the coming years.
North America Dominates the Market and is Expected to Follow the Same Trend Over the Forecast Period
North America currently dominates the anesthesia drugs market and is expected to continue its stronghold for a few more years. The US anesthesia market is the largest regional market in the world. This market is driven by factors, such as the increasing number of surgeries, rising aging population with increasing chronic conditions, and advancements in anesthesia technologies.
Competitive Landscape
The anesthesia drugs market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with rising drug approvals, mid-size to smaller companies are increasing their market presence by introducing new ingredients with fewer prices. Companies, like Baxter, Abbott Laboratories, AstraZeneca, Roche Holding AG, and Boehringer Ingelheim, hold substantial market shares in the anesthesia drugs market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Number of Surgeries
4.2.2 New Approvals of Anesthetic Drugs
4.2.3 Reduction in the Cost of Newly Invented Drugs
4.3 Market Restraints
4.3.1 Side Effects of General Anesthetics
4.3.2 Lack of Skilled-Anesthetics
4.3.3 Regulatory Issues
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug Type
5.1.1 General Anesthesia Drugs
5.1.1.1 Propofol
5.1.1.2 Sevoflurane
5.1.1.3 Desflurane
5.1.1.4 Dexmedetomidine
5.1.1.5 Remifentanil
5.1.1.6 Midazolam
5.1.1.7 Other General Anesthesia Drugs
5.1.2 Local Anesthesia Drugs
5.1.2.1 Bupivacaine
5.1.2.2 Ropivacaine
5.1.2.3 Lidocaine
5.1.2.4 Chloroprocaine
5.1.2.5 Articaine
5.1.2.6 Benzocaine
5.1.2.7 Local Anesthesia Drugs
5.2 By Route of Administration
5.2.1 Inhalation
5.2.2 Injection
5.2.3 Other Routes of Administration
5.3 By Application
5.3.1 General Surgeries
5.3.2 Plastic Surgery
5.3.3 Cosmetic Surgeries
5.3.4 Dental Surgeries
5.3.5 Other Applications
5.4 Geography
5.4.1 North America
5.4.1.1 US
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 UK
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Baxter
6.1.2 Hospira
6.1.3 Abbott Laboratories
6.1.4 AstraZeneca
6.1.5 F. Hoffmann-La Roche AG
6.1.6 B. Braun Melsungen AG
6.1.7 AbbVie Inc.
6.1.8 Boehringer Ingelheim International GmbH
6.1.9 Eisai Co. Ltd
6.1.10 Fresenius SE & Co. KGaA
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug Type
General Anesthesia Drugs
Propofol
Sevoflurane
Desflurane
Dexmedetomidine
Remifentanil
Midazolam
Other General Anesthesia Drugs
Local Anesthesia Drugs
Bupivacaine
Ropivacaine
Lidocaine
Chloroprocaine
Articaine
Benzocaine
Other Local Anesthesia Drugs
By Route of Administration
Inhalation
Injection
Other Routes of Administration
By Application
General Surgeries
Plastic Surgery
Cosmetic Surgeries
Dental Surgeries
Other Applications
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Ambulatory EHR Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 07-06-2019
Market Overview
The factors propelling the growth of the ambulatory EHR market include the rising adoption of EHR solutions in developed markets, increasing need for fluid movement of healthcare information and technological advancements, and government initiatives to maintain and enhance patient health record portals.
In the past decade, it was observed that paper-based records were being phased out at a rapid pace, with digitization and virtualization creating multiple growth opportunities for the better management of patient records across the chain of hospitals and research centers in healthcare. Thus, there has been increasing adoption by multiple healthcare centers across developed markets, which was found to be one of the major drivers of the market studied.
The use of ambulatory EHR has been beneficial across several developed markets in Europe, East Asia, and North America, in the recent years. Some countries in Europe and Asia-Pacific, such as Demark, England, Finland, the Netherlands, and New Zealand, have consistently shown high usage of ambulatory EHR.
There are also increasing investments being made by governments to maintain and enhance patient health record portals. The federal government in the United States has made several investments to transform the US healthcare industry into the electronic age.
Scope of the Report
As per the scope of the report, ambulatory care involves patients who do not stay overnight for disease treatment in any healthcare setting. EHR is a patient’s record that helps authorized users to securely access the available information about the patient. The information on EHR can be shared across different healthcare settings through network connected systems, which allows physicians to take better decisions and provide improved coordinated care for patients. The EHR developed for ambulatory services are simpler than inpatient EHRs, as they deal with a single practice and its patients, and are used in outpatient care facilities and smaller practices.
Key Market Trends
Cloud-based Solutions Segment, By Delivery Mode, is Expected to Grow the Fastest
The cloud-based solutions sub-segment is expected to occupy a high share, due to its cost-effective services and advantages of user-friendly software models. Patient information is stored and managed using these cloud-based electronic health records, making them more secure. It also allows physicians and medical practitioners to control access to sensitive information.
On-premise storage has also evolved over the past several years. These systems require the installation of specific hardware and software. Therefore, cloud-based solutions are the most commonly adopted solutions, since these are much cheaper when compared to on-premise solutions.
Asia-Pacific holds the Fastest Growth and is Expected to Follow the Same Trend over the Forecast Period
Asia-Pacific is expected to be the fastest-growing region, due to high investments by governments, non-profit entities, and the private sector, in EHR systems. The factors responsible for the growth include the growing ageing population and rising incidence of chronic diseases in various countries, such as India and China. In addition, the region has a better hospital network and training programs that increase the presence of general practitioners, and an increase in ambulatory care services.
Competitive Landscape
Most of the companies present in the market are efficient at the technological front, but require significant support for enhancing their services and expanding their businesses. Thus, mergers and acquisitions offer significant opportunities to gain the attention of a large number of providers and hospitals across developed regions.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Adoption of EHR Solutions in Developed Markets
4.2.2 Increasing Need for Fluid Movement of Healthcare Information and Technological Advancements
4.2.3 Government Initiatives to Maintain and Enhance Patient Health Record Portals
4.3 Market Restraints
4.3.1 Inconsistent EHR Adoption across Emerging Markets
4.3.2 Regulatory Barriers
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Application
5.1.1 Practice Management
5.1.2 Patient Management
5.1.2.1 Interventional/Surgical Simulators
5.1.3 E-prescribing
5.1.4 Referral Management
5.1.5 Population Health Management
5.1.6 Other Applications
5.2 By Delivery Mode
5.2.1 Cloud-based Solutions
5.2.2 On-premise Solutions
5.3 By Practice Size
5.3.1 Large Practices
5.3.2 Medium-sized Practices
5.3.3 Small Practices
5.4 By End User
5.4.1 Hospital-owned Ambulatory Centers
5.4.2 Independent Ambulatory Centers
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Allscripts Healthcare Solutions Inc.
6.1.2 Aprima Medical Software Inc.
6.1.3 Athenahealth Inc.
6.1.4 Cerner Corporation
6.1.5 eClinicalWorks
6.1.6 Epic Systems Corporation
6.1.7 Greenway Health
6.1.8 Medhost
6.1.9 Medical Information Technology Inc.
6.1.10 Nextgen Healthcare Information Systems LLC
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Application
Practice Management
Patient Management
Interventional/Surgical Simulators
E-prescribing
Referral Management
Population Health Management
Other Applications
By Delivery Mode
Cloud-based Solutions
On-premise Solutions
By Practice Size
Large Practices
Medium-sized Practices
Small Practices
By End User
Hospital-owned Ambulatory Centers
Independent Ambulatory Centers
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Alzheimer’s Disease Diagnostics and Therapeutics Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 114 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 114 pages
- Published: 07-06-2019
Market Overview
The global Alzheimer’s disease diagnostics and therapeutics market was valued at USD 7,537.4 million in 2018, and is estimated to be valued at USD 11,138.2 million in 2024, witnessing a CAGR of 6.7%. The key factors propelling the growth of this market are investment in biomarkers for drug development, increasing pipeline drug development, increasing sophisticated diagnostics for early detection, along with more precise drug development, and emerging novel diagnostics technologies.
Alzheimer’s disease is one of the most prevalent types of dementia that occurs worldwide. According to the Alzheimer’s disease facts and figures, it is estimated that in every 33 seconds, a new case of Alzheimer’s disease occurs, leading to high prevalence of the disease, of almost 35 million patients, around the world. The development of clinical diagnostics and therapeutics for Alzheimer’s disease (AD) and other neurodegenerative conditions is becoming very important. In about 10-15% cases, the clinical diagnosis of AD is inaccurate. So, certain biomarkers that may improve the accuracy of the diagnosis are used. Biomarkers are neurochemical indicators used to determine the risk or prevalence of the disease.
Investing in biomarkers for drug development and early detection of AD acts as a major driver, and fuels the growth of the Alzheimer’s disease diagnostics and therapeutics market, globally.
Scope of the Report
As per the scope of the report, Alzheimer’s disease (AD) is a progressive, degenerative disorder that attacks the brain’s nerve cells or neurons, resulting in loss of memory, thinking and language skills, and behavioural changes.
Key Market Trends
Cholinesterase Inhibitors are Expected to hold the Highest Market Share in the Therapeutics Segment
In the therapeutics segment of the Alzheimer’s disease diagnostics and therapeutics market. Cholinesterase inhibitors are believed to have the largest market size and are expected to witness a CAGR of 6.4% during the forecast period.
Cholinesterase inhibitors are used for the treatment of Alzheimer’s. These cholinesterase inhibitors are approved by the US FDA. Most physicians and perhaps most patients consider cholinergic drugs. Donepezil, galantamine, and rivastigmine are the generic names of cholinesterase inhibitors, which are likely to be the first-line pharmacotherapy choice for mild to moderate Alzheimer’s disease. These drugs have somewhat different pharmacological properties, but all of them work by the same mechanism, which involves inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase.
The market is dominated by leading brands, such as Aricept, Exelon, and Reminyl; Aricept, whose active ingredient is a cholinesterase inhibitor, holds the largest market share. Several clinical trials are ongoing on cholinesterase inhibitors to increase drug efficacy and decrease adverse effects. Hence, oeing to the developments, the cholinesterase inhibitor drugs market is expected to grow during the forecast period.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America currently dominates the market for Alzheimer’s disease diagnostics and therapeutics ,and is expected to continue its stronghold for a few more years. The United States holds the largest share of the global Alzheimer’s disease diagnostics and therapeutics market. According to the Alzheimer’s Association, more than 5 million Americans suffer from Alzheimer’s, as of 2017. The United States is considered to be the global leader in Alzheimer’s disease intervention and management. America has a large pool of biopharmaceutical companies, which cumulatively have 85 drugs for combating Alzheimer’s disease in various stages of the pipeline. Hence, the market is expected to register a healthy CAGR over the forecast period.
Competitive Landscape
The Alzheimer’s disease diagnostics and therapeutics market is moderately competitive and consists of several major players. With technological advancements and product innovation, mid-size to smaller companies are increasing their market presence, by introducing new technologies with better results. Companies, like F. Hoffmann-La Roche, Novartis AG, Merck & Co., Pfizer Inc., and Eli Lily & Co., hold a substantial market share in the Alzheimer’s disease diagnostics and therapeutics market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Investment in Biomarkers for Drug Development
4.2.2 Increasing Pipeline Drug Development
4.2.3 Increasing Sophisticated Diagnostics for Early Detection and More Precise Drug Development
4.2.4 Emerging Novel Diagnostic Technologies
4.3 Market Restraints
4.3.1 Early Diagnosis of the Indication is Challenging
4.3.2 Decline in the Market Due to Failures of Late-stage Drugs
4.3.3 Lack of Surrogate Markers for Drug Discovery and Drug Development
4.3.4 Insufficient Research Funding and Lengthy, Expensive, and Uncertain Process
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Therapeutics
5.1.1 Cholinesterase Inhibitors
5.1.2 NMDA Receptor Antagonists
5.1.3 Other Therapeutics
5.2 By Diagnostics
5.2.1 Brain Imaging
5.2.2 CFS Test for Alzheimer’s Disease
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 F. Hoffmann-La Roche
6.1.2 Novartis AG
6.1.3 Merck & Co. Inc
6.1.4 Pfizer Inc
6.1.5 Eisai Co. Ltd
6.1.6 Biogen Inc
6.1.7 Johnson & Johnson
6.1.8 Eli Lilly & Company
6.1.9 Amarantus Bioscience Holdings Inc
6.1.10 Diagenic ASA
6.1.11 Navidea Biopharmaceuticals
6.1.12 GE Healthcare
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Therapeutics
Cholinesterase Inhibitors
NMDA Receptor Antagonists
Other Therapeutics
By Diagnostics
Brain Imaging
CFS Test for Alzheimer’s Disease
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Alpha Emitter Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 07-06-2019
Market Overview
The global alpha emitter market was valued at USD 506.5 million in 2018, and it is estimated to be valued at USD 3302.99 million by 2024 while witnessing a CAGR of 36.69% over the forecast period of 2019-2024. Certain factors that are driving the market growth include increased awareness about the potential benefits of targeted alpha therapy, and the growing number of patients with cardiac and cancer ailments.
Targeted anticancer or alpha therapy (TAT) is gaining popularity with the increasing prevalence of cancer and cardiovascular diseases. Consumers are now increasingly aware of the potential benefits of targeted therapies to cure such ailments.
Furthermore, radioimmunotherapy with short-ranged and high-efficiency α-particles is a striking and promising treatment approach. α-particles have an advantage in targeted therapy because of their exceptionally high cell-killing ability. However, regulatory requirements pose a hurdle to translational research and clinical investigations. For instance, in the United States, all pharmacologic agents, including diagnostic radiopharmaceuticals and radiotherapeutics, undergo regulatory oversight by the FDA. Similarly, radiopharmaceuticals face additional scrutiny and undergo unique regulatory and approval pathways, across the world.
Scope of the Report
In therapeutic radiopharmaceuticals, radionuclides with alpha emitters play a significant role in treating cancers. Properties of alpha emitters have led to exert profound differences between this field and other fields of nuclear medicine. Due to their short range and high LET (deposit energy in a unit length of their pathway), alpha particles have remarkably been considered into medical research.
Key Market Trends
Medical Application in Ovarian Cancer is Expected to Observe the Highest Growth Rate over the Forecast Period
The ovarian cancer segment in the alpha emitter market is expected to witness the highest CAGR of 35.63% during the forecast period.
The growth rate is attributed to an increasing number of new diagnosis cases. As per the estimates of the American Cancer Society, in 2018, around 22,240 women were expected to receive a new diagnosis of ovarian cancer, and about 14,070 women would die from ovarian cancer.
Ovarian cancer uses radioimmunotherapy as locally injected adjuvant therapy. Trials have evaluated the practice of complete abdominal or moving-strip external-beam radiotherapy (EBRT) or non-specific i.p. radiotherapy, with colloid preparations of Au-198 or P-32 as adjuvant therapies.
Moreover, the adoption of targeted alpha therapy with higher LET and shorter wavelengths has been promising in the treatment process. This trend is expected to gain traction in the near future. In addition, a recent Phase I clinical trial involving At-211-MX35 F (ab′) showed significant efficacy, as therapeutic doses reached their targets in patients with ovarian cancer.
North America Dominates the Market and is Expected to do Same in the Forecast Period
North America currently dominates the alpha emitter market, and it is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the fact that the increase in cardiac and neurological chronic diseases is the major driving factor for the market growth in the region. For instance, 223RaCl2 (Xofigo) is the first alpha-emitting radioisotope to gain registration in the United States for palliative therapy of prostate cancer bone metastases through indirect physiological targeting.
Moreover, according to the National Cancer Institute, the number of new cases of melanoma was 21.8 per 100,000 men and women, per year. Similarly, the rising prevalence of cancer is making it imperative for the healthcare professionals across Canada to increase the radiotherapy utilization for cancer treatment. This is directly affecting the growth of the alpha emitter market in the country.
Competitive Landscape
The global alpha emitter market is less competitive and consists of very few major players. Companies, like IBA Radiopharma Solutions, Bayer AG, Alpha Tau Medical Ltd, Actinium Pharmaceutical Inc., Telix Pharmaceuticals Ltd, RadioMedix Inc., and Fusion Pharmaceuticals hold the substantial market share in the global alpha emitter market.
A number of developments have been taking place in the market over recent years.
For example, in November 2017, Actinium Pharmaceuticals launched the AWE Program, aka Actinium Warhead Enabling Program, to enable collaborations based on its Actinium-225 Technology Platform. Whereas, in November 2017, Alpha Tau Medical entered a collaboration with IRST Italy to treat its first cancer patients. This is significant progress toward international expansion. This is also expected to enable the availability of Alpha DaRT radiotherapy all across Europe, Asia, as well as the United States.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Awareness About the Potential Benefits of Targeted Alpha Therapy
4.2.2 Increasing Number of Patients with Cardiac and Cancer Ailments
4.3 Market Restraints
4.3.1 Short Half-life of Radiopharmaceuticals
4.3.2 Stringent Regulatory Framework and Reimbursement Issues
4.3.3 Need for High Capital Investment
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 Type of Radionuclide
5.1.1 Terbium (Tb-149)
5.1.2 Astatine (At-211)
5.1.3 Bismuth (Bi-212)
5.1.4 Actinium (Ac-225)
5.1.5 Radium (Ra-223)
5.1.6 Lead (Pb-212)
5.1.7 Bismuth (Bi -213)
5.2 Medical Application
5.2.1 Glioma
5.2.2 Melanoma
5.2.3 Pancreatic Cancer
5.2.4 Ovarian Cancer
5.2.5 Thyroid
5.2.6 Bone Metastasis
5.2.7 Lymphoma
5.2.8 Endocrine Tumors
5.2.9 Other Medical Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 Actinium Pharmaceutical Inc.
6.1.2 Alpha Tau Medical Ltd
6.1.3 Bayer AG
6.1.4 Fusion Pharmaceuticals
6.1.5 IBA Radiopharma Solutions
6.1.6 RadioMedix Inc.
6.1.7 Telix Pharmaceuticals Ltd
7. Market Opportunities and Future Trends
Market Segmentation
- Type of Radionuclide
Terbium (Tb-149)
Astatine (At-211)
Bismuth (Bi-212)
Actinium (Ac-225)
Radium (Ra-223)
Lead (Pb-212)
Bismuth (Bi -213)
Medical Application
Glioma
Melanoma
Pancreatic Cancer
Ovarian Cancer
Thyroid
Bone Metastasis
Lymphoma
Endocrine Tumors
Other Medical Applications
Geography
North America
United States
Canada
Mexico - Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America